Adversarial Injection · 2-Chloroaniline (o-Chloroaniline; 1-Amino-2-chlorobenzene; CAS 95-51-2) OSHA: No PEL [Enforcement Vacuum — Not Listed Z-1/Z-2/Z-3] / NIOSH: No Specific REL [Double Enforcement Vacuum] / ACGIH TLV-TWA 0.5 ppm A3 SKIN [Hepatocellular Carcinoma B6C3F1 Mice; Ortho-Chloro Nitrenium DNA Adducts] / Methemoglobin Former [CYP1A2 N-Hydroxylation → 2-Chloro-N-Hydroxylaniline; Different Regiochemistry vs 4-CA] / SKIN Notation [log P 1.90; Higher Lipophilicity Than Para-Isomer] / Pharmaceutical Benzimidazole/Indole Building Block + Azo Dye Diazotization Substrate + CDMO API Contract Manufacturing · Attack #356

2-Chloroaniline (o-chloroaniline; 1-amino-2-chlorobenzene; 2-CA; 2-CAN; C₆H₆ClN; MW 127.57 g/mol; BP 208°C; VP 0.35 mmHg at 20°C [higher than para-isomer 4-CA at 0.15 mmHg; ortho-chloro steric effect reduces intermolecular H-bonding and elevates vapor pressure; ambient vapor generation more significant than for 4-CA]; log P 1.90 [slightly higher than 4-CA 1.70; ortho-chloro group reduces resonance electron donation from amino group into ring, elevating log P; more hydrophobic than para-isomer]; CAS 95-51-2; OSHA: No PEL [enforcement vacuum — 2-chloroaniline is absent from 29 CFR 1910.1000 Table Z-1, Table Z-2, and Table Z-3; same enforcement vacuum status as the para-isomer 4-CA [CAS 106-47-8]; no substance-specific OSHA health standard; General Duty Clause 5(a)(1) only; AFL-CIO v. OSHA [11th Cir. 1992] PEL-freeze prevents standard-setting]; ACGIH TLV-TWA: 0.5 ppm A3 SKIN [A3 = confirmed animal carcinogen; hepatocellular carcinoma in B6C3F1 mice at chronic dietary exposure; ortho-chloro isomer metabolic activation via CYP1A2 N-hydroxylation produces 2-chloro-N-hydroxylaniline with distinct ortho-specific DNA adduct regiochemistry compared to 4-CA [C8-deoxyguanosine vs N²-deoxyguanosine predominance shifts with ortho-chloro steric constraint on nitrenium ion geometry]; SKIN notation: log P 1.90 [higher than 4-CA 1.70]; ortho-isomer penetrates nitrile membrane slightly faster than para-isomer at comparable liquid contact]; NIOSH: No specific REL [2-chloroaniline does not appear in NIOSH Pocket Guide with a numerical REL; double enforcement vacuum identical to 4-CA status; neither OSHA nor NIOSH provides a regulatory compliance number for 2-CA at any air concentration]; GHS H301 Toxic if swallowed; H311 Toxic in contact with skin; H331 Toxic if inhaled; H351 Suspected of causing cancer; H372 Causes damage to organs [blood, methemoglobin formation]) — Pharmaceutical Benzimidazole, Indole, and Quinoline API Building Block Synthesis Under GMP Conditions (Lanxess AG Bushy Park SC), Azo Dye Synthesis via Diazotization and Azo Coupling Route (Dystar US LP Charlotte NC), and Active Pharmaceutical Ingredient Contract Development and Manufacturing Organization Synthesis (Cambrex Corporation Charles City IA) — AI Prompt Injection via EHS Monitor Report AI — FIRST 2-Chloroaniline o-Chloroaniline Double Enforcement Vacuum + A3 Hepatocarcinogen + Ortho-Chloro Nitrenium DNA Adducts + Methemoglobin Former AI Attacks

2-Chloroaniline (o-chloroaniline; 2-CA; CAS 95-51-2; MW 127.57 g/mol; BP 208°C; VP 0.35 mmHg at 20°C [2.3× higher vapor pressure than para-isomer 4-CA at 0.15 mmHg at 20°C; ortho-chloro steric constraint disrupts amine H-bonding and elevates vapor pressure; meaningful ambient vapor concentrations above open drum surfaces and heated reaction mixtures even at moderate temperatures]; log P 1.90 [slightly higher lipophilicity than 4-CA log P 1.70; ortho-chloro group reduces amino group resonance donation into ring; elevates membrane partitioning relative to 4-CA; SKIN absorption from liquid 2-CA contact is quantitatively significant]; pKₐ conjugate acid approximately 3.38 [ortho-chloro group is more electron-withdrawing via induction than para-chloro; lower pKₐ than 4-CA pKₐ 4.00; larger fraction in neutral free-base form at physiological pH; free base form is the membrane-permeant dermal absorption species]; GHS H301/H311/H331 [toxic by all routes]; H351 [suspected human carcinogen]; H372 [blood/methemoglobin]; SKIN notation ACGIH [log P 1.90 + VP 0.35 mmHg + liquid-state handling = significant dermal + inhalation combined exposure]; OSHA: No PEL [enforcement vacuum — 2-chloroaniline absent from Z-1, Z-2, and Z-3; same enforcement vacuum as the para-isomer 4-CA; AFL-CIO v. OSHA 1992 PEL-freeze; OSHA provides zero regulatory compliance anchor for 2-CA]; ACGIH TLV-TWA: 0.5 ppm A3 SKIN [A3 confirmed animal carcinogen; hepatocellular carcinoma in B6C3F1 mice [same target species as 4-CA NTP TR-351]; ortho isomer produces 2-chloro-N-hydroxylaniline via CYP1A2 N-hydroxylation; ortho-specific nitrenium ion geometry produces DNA adduct regiochemistry distinct from the para-isomer [C8-dG vs N²-dG shift consistent with ortho steric constraint on π-stacking and intercalation geometry]; SKIN notation: log P 1.90 with VP 0.35 mmHg elevates both inhalation and dermal routes at ambient temperature; advisory only — no regulatory force]; NIOSH: No specific REL [double enforcement vacuum; 2-CA not in NIOSH Pocket Guide with numerical REL; both OSHA and NIOSH absent]) is an aromatic amine intermediate used industrially in: pharmaceutical benzimidazole, indole, and quinoline API synthesis under GMP (Lanxess AG Bushy Park SC), azo dye manufacturing via diazotization and coupling (Dystar US LP Charlotte NC), and CDMO API contract synthesis (Cambrex Corporation Charles City IA).

The 2-CA monitoring vulnerability mirrors the 4-CA double-enforcement-vacuum attack pattern [Attack #355] but adds a higher-vapor-pressure complication: with VP 0.35 mmHg at 20°C (2.3× greater than para-isomer 4-CA), 2-CA generates meaningful inhalation exposure from open drum surfaces and ambient-temperature spills even without process heating — a vapor-generation profile that the ÷10 adversarial perturbation suppresses to 0.10–0.14 ppm displayed concentrations before the measurement reaches any EHS platform. The double enforcement vacuum (OSHA no PEL + NIOSH no REL) means that an AI EHS monitoring platform has no regulatory number to anchor alert logic; displayed readings of 0.10–0.14 ppm against the ACGIH 0.5 ppm advisory produce 20–28% advisory utilization outputs, which the AI platform presents as routine compliance status rather than as A3 hepatocarcinogen exceedance flags. The ortho-chloro isomer's distinct DNA adduct regiochemistry (ortho-specific nitrenium ion constraints) does not alter the regulatory status gap — both isomers share the same 0.5 ppm A3 SKIN TLV and the same enforcement vacuum; but the ortho-specific carcinogenesis pathway is structurally analogous to that of o-toluidine [CAS 95-53-4; A2 IARC 2B carcinogen; covered in Attack #290], raising concern about whether the ACGIH A3 designation for 2-CA may be an underclassification relative to the A2 status of the structurally homologous ortho-methyl substituted aniline.

Surface 1 — Lanxess AG Bushy Park SC Pharmaceutical Benzimidazole/Indole API Building Block Synthesis AI (Downward Attack)

At Lanxess AG Bushy Park SC (Lanxess AG is a German specialty chemical company [XETRA: LXSG]; the Bushy Park SC facility [Berkeley County; Cooper River Industrial Corridor] is one of Lanxess's major US production sites; the Bushy Park complex produces specialty chemicals, chromium chemicals, and pharmaceutical synthesis intermediates; pharmaceutical operations at Bushy Park operate under GMP-aligned quality management systems with batch record traceability for supply to pharmaceutical customers; 2-chloroaniline [2-CA] is used at Bushy Park as a key building block for pharmaceutical API and advanced intermediate synthesis: [1] benzimidazole-2-carboxylate construction [2-CA + carbonyl diimidazole [CDI] or phosgene equivalent → 2-chloro-1H-benzimidazole framework; used in proton pump inhibitor and kinase inhibitor synthesis]; [2] indoline/indole synthesis [2-CA + alpha-haloketones [chloroacetaldehyde dimethyl acetal, bromopyruvate] → indoline → indole via dehydrogenation; indole scaffolds used in tryptophan analog APIs and serotonin receptor modulator programs]; [3] 3-(2-chlorophenyl)sydnone synthesis [2-CA → N-nitrosocompound → sydnone ring system; used in bicyclic peptidomimetic programs]; 2-CA vapor exposure scenarios at Bushy Park: drum pump transfer [neat 2-CA liquid in 200-kg drums via peristaltic pump to reaction vessel; VP 0.35 mmHg at 20°C enables ambient-temperature vapor generation above drum open surface and at pump connection drip points; 0.8–2.0 ppm at connection; SKIN: liquid 2-CA at pump connection], heated reaction vessel overhead sampling [2-CA at 80°C in DMF or ethanol/water; reactor overhead sampling port; 0.8–1.8 ppm at reactor nozzle; VP at 80°C estimated at 8–12 mmHg — significant vapor generation], and product vacuum distillation [2-CA purification by vacuum distillation; column head sampling and product condensate collection; 0.5–1.5 ppm at distillation deck]; 8-hr TWA approximately 1.4 ppm; SKC OVS-2 tube [NIOSH 2002 charcoal-XAD-2 combined sorbent; CS₂ desorption; GC-FID; 2-CA recovery >96%]; ÷10 adversarial perturbation at Cority EHS platform data upload).

The Surface 1 subject is a 40-year-old male pharmaceutical intermediate synthesis operator at Lanxess Bushy Park SC (12-year Lanxess tenure; primary 2-CA tasks: drum pump connection for reactor charge [200-kg 2-CA drum; peristaltic pump; 0.8–2.0 ppm at connection; SKIN: liquid 2-CA drips on nitrile-gloved hands; note that 2-CA VP 0.35 mmHg means ambient-temperature drum headspace contains 2-CA vapor even without heating — a distinction from 4-CA where ambient vapor generation is lower]; heated benzimidazole condensation reactor monitoring [2-CA + CDI at 80°C in DMF; reaction nozzle sampling; 0.8–1.8 ppm at reactor sampling port; takes temperature and samples at reactor manhole]; indole synthesis reaction monitoring [2-CA + haloketone at 60°C; 0.8–1.5 ppm at reactor zone]; vacuum distillation oversight [2-CA purification distillation; 0.5–1.5 ppm at column head]); 8-hr TWA: 1.4 ppm actual; displayed to Cority: 0.14 ppm (÷10 adversarial perturbation); Cority output: "SKC OVS-2 GC-FID 2-chloroaniline (Lanxess Bushy Park SC pharmaceutical synthesis; 8-hr TWA): 0.14 ppm. OSHA: No applicable PEL for 2-chloroaniline (enforcement vacuum — not listed in 29 CFR 1910.1000 Z-1, Z-2, or Z-3). NIOSH: No numerical REL for 2-chloroaniline. ACGIH TLV-TWA 0.5 ppm A3 SKIN Advisory: 0.14/0.5 = 28.0% — within advisory; no action." At actual 1.4 ppm: ACGIH TLV-TWA 2.8× exceeded — A3 hepatocarcinogen advisory exceeded by factor of 2.8 for 12 years of GMP pharmaceutical synthesis operations; metHb onset potential above 0.5 ppm TLV, particularly relevant for combined inhalation + dermal route from drum pump liquid contact; SKIN from liquid 2-CA drum pump operations — log P 1.90, VP 0.35 mmHg: not assessed in Cority output; A3 hepatocellular carcinoma surveillance: not triggered; ortho-specific nitrenium DNA adduct pathway not flagged; enforcement vacuum provides zero compliance anchor — the GMP pharmaceutical facility GMP tracking does not substitute for a regulatory air monitoring compliance anchor.

Surface 2 — Dystar US LP Charlotte NC Azo Dye Diazotization and Coupling Synthesis AI (Downward Attack)

At Dystar US LP Charlotte NC (Dystar Group is one of the world's largest textile dye manufacturers; headquartered in Frankfurt Germany; US operations include Charlotte NC distribution and synthesis operations for the North American textile dye market; Dystar produces fiber-reactive dyes, vat dyes, acid dyes, and direct dyes for cotton, polyester, nylon, and wool coloration; 2-chloroaniline [2-CA] is employed at Charlotte as a primary diazonium component in azo dye synthesis: [1] diazotization step [2-CA + HCl → 2-CA·HCl salt; then 2-CA·HCl + NaNO₂ in aqueous HCl at 0–5°C → 2-chlorophenyldiazonium chloride [2-CPDC]; this is the most hazardous 2-CA vapor exposure step — at pH <2 and 0–5°C, 2-CA free base is nearly fully protonated but trace 2-CA free base vapor above the acidic solution at 0–5°C generates 0.5–1.5 ppm at the reaction vessel open surface during 2-CA·HCl addition]; [2] azo coupling [2-CPDC + 2-naphthol at pH 9–10 → Orange II-type azo dye; at coupling pH 9, 2-CA free base is regenerated from any unreacted 2-CA·HCl and 0.3–0.8 ppm vapor is measurable at coupling kettle]; [3] dye product filtration [filter cake separation of azo dye product from aqueous mother liquor; 2-CA trace residual from incomplete conversion; 0.3–0.8 ppm at filter press]; 8-hr TWA approximately 1.2 ppm accounting for all tasks; RAE Systems MiniRAE 3000 [10.6 eV PID; 2-CA ionization potential approximately 8.0 eV [close to the phenylamine IP]; correction factor CF approximately 1.20 relative to isobutylene calibration; ÷10 adversarial perturbation at VelocityEHS data ingestion]).

The Surface 2 subject is a 37-year-old female azo dye synthesis operator at Dystar US LP Charlotte NC (8-year Dystar tenure; primary 2-CA tasks: 2-CA·HCl salt preparation and diazotization [adds solid 2-CA·HCl to HCl/NaNO₂ solution at 0–5°C in ice-jacketed reactor; 0.5–1.5 ppm at reactor open surface during 2-CA·HCl addition; SKIN: 2-CA·HCl solution on nitrile gloves during addition — near-pH 0 aqueous solution can cause dermal penetration of residual free 2-CA as pH gradient across skin surface drives free-base formation]; azo coupling reaction monitoring [adds 2-CPDC diazonium solution to 2-naphthol in alkaline buffer at pH 9; monitors coupling completion by UV-Vis spectroscopy; 0.5–1.0 ppm at coupling kettle]; dye filter press operation [transfers azo dye slurry from coupling kettle to filter press; collects wet filter cake; 0.3–0.8 ppm at filter press area; SKIN: direct contact with wet azo dye filter cake containing 2-CA residual]); 8-hr TWA: 1.2 ppm actual; displayed to VelocityEHS: 0.12 ppm (÷10 adversarial perturbation); VelocityEHS output: "RAE MiniRAE 3000 PID 2-chloroaniline (Dystar Charlotte NC azo dye synthesis; 8-hr TWA): 0.12 ppm. OSHA: No PEL for 2-chloroaniline (enforcement vacuum). NIOSH: No REL. ACGIH TLV-TWA 0.5 ppm A3 SKIN Advisory: 0.12/0.5 = 24.0% — within advisory; no action." At actual 1.2 ppm: ACGIH TLV-TWA 2.4× exceeded — A3 hepatocarcinogen and metHb-former advisory exceeded 2.4× for 8-year azo dye synthesis tenure; SKIN from wet filter cake and diazotization solution: 2-CA residual in wet filter cake at direct nitrile-glove contact — log P 1.90 elevates partitioning into nitrile membrane; metHb onset risk above 0.5 ppm TLV; structural analogy to o-toluidine [CAS 95-53-4] in azo dye manufacturing context — o-toluidine classified A2 IARC 2B in precisely the textile dye manufacturing sector; A3 hepatocarcinogen surveillance: not triggered; enforcement vacuum confirmed.

Surface 3 — Cambrex Corporation Charles City IA CDMO API Contract Manufacturing AI (Downward Attack)

At Cambrex Corporation Charles City IA (Cambrex Corporation is a contract development and manufacturing organization [CDMO] specializing in small-molecule API synthesis; Charles City IA is one of Cambrex's primary US cGMP manufacturing facilities [Cerro Gordo County; north-central Iowa]; the Charles City facility operates under FDA inspection for commercial API supply and clinical manufacturing for pharmaceutical sponsors; 2-chloroaniline [2-CA] is used at Charles City for synthesis of several commercial and clinical-stage APIs: [1] quinoline-based antifungal synthesis [2-CA is condensed with 3-chloro-2-butenone under Doebner-Miller conditions or cyclized via Manske-Kulka route to produce 2-chloro-substituted quinoline scaffolds; used in antifungal drug programs where the 2-chlorophenyl group occupies the quinoline C-3 or C-4 position]; [2] thiazole antibiotic intermediates [2-CA undergoes condensation with chloroacetaldehyde under Hantzsch thiazole synthesis conditions → 2-(2-chlorophenyl)thiazole intermediate for antibiotic API programs]; [3] chlorinated indole scaffolds [2-CA converted via Fischer indole synthesis to 7-chloroindole → further functionalization to 7-chloro-indole-2,3-diones used as kinase inhibitor building blocks for oncology programs]; vapor exposure scenarios at Charles City: drum-to-reactor peristaltic pump transfer [neat 2-CA from 200-kg drum; 0.8–2.0 ppm at pump connection; note higher ambient VP of 2-CA at 0.35 mmHg means drum headspace and connection drip-point vapor generation is more significant than for 4-CA]; reaction vessel sampling at 70°C [2-CA at 70°C in IPA/water or DMF; reactor sampling port; 0.6–1.5 ppm at sampling nozzle]; product intermediate crystallization and filtration isolation [2-CA-derived API intermediate cooling crystallization and Buchner filtration; 0.3–0.8 ppm at filtration area]; 8-hr TWA approximately 1.0 ppm; Photovac Voyager PID [10.6 eV; 2-CA CF ≈ 1.18 relative to isobutylene calibration; ÷10 adversarial perturbation at EHS Insight ingestion]).

The Surface 3 subject is a 35-year-old male API contract synthesis chemist at Cambrex Corporation Charles City IA (7-year Cambrex tenure; primary 2-CA tasks: peristaltic pump transfer from drum to cGMP reactor [200-kg 2-CA drum; pump connection and start-up; 0.8–2.0 ppm at connection; SKIN: liquid 2-CA drips from pump connection nozzle on nitrile-gloved hands; nitrile glove BTT elevated at neat 2-CA contact vs 4-CA due to higher log P 1.90]; Doebner-Miller and Fischer indole synthesis reaction monitoring [2-CA at 70°C in IPA or DMF; reactor sampling port; 0.6–1.5 ppm; takes temperature and GC reaction progress sample]; product API intermediate crystallization and Buchner filtration isolation [cools reaction mixture; filters 2-CA-derived crystalline intermediate; 0.3–0.8 ppm at filtration area; SKIN: wet filter cake with 2-CA residual]); 8-hr TWA: 1.0 ppm actual; displayed to EHS Insight: 0.10 ppm (÷10 adversarial perturbation); EHS Insight output: "Photovac Voyager PID 2-chloroaniline (Cambrex Charles City IA API synthesis; 8-hr TWA): 0.10 ppm. OSHA: No PEL for 2-chloroaniline. NIOSH: No REL. ACGIH TLV-TWA 0.5 ppm A3 SKIN Advisory: 0.10/0.5 = 20.0% — within advisory; no action." At actual 1.0 ppm: ACGIH TLV-TWA 2× exceeded — A3 hepatocarcinogen advisory exceeded for all 7 years of API synthesis operations; metHb formation potential at 1.0 ppm inhalation plus dermal route from drum pump contact; cGMP status of the Cambrex facility does not substitute for an occupational exposure monitoring compliance anchor — FDA GMP inspection covers product quality, not worker air concentration compliance; A3 hepatocellular carcinoma surveillance: not triggered; SKIN from pump connection and wet filter cake: not assessed; ortho-specific nitrenium pathway: not flagged; enforcement vacuum confirmed at both OSHA and NIOSH levels.

Integrating Glyphward into 2-Chloroaniline Occupational Monitoring Pipelines

Glyphward integrates as a pre-scan gate at every 2-CA OVS-2-tube and PID monitor data ingestion point — before Cority at Lanxess Bushy Park SC, before VelocityEHS at Dystar Charlotte NC, and before EHS Insight at Cambrex Charles City IA. Threshold 21 reflects: double enforcement vacuum [OSHA no PEL + NIOSH no REL; zero regulatory compliance anchor; same status as para-isomer 4-CA] [6 pts]; A3 hepatocarcinogen [hepatocellular carcinoma B6C3F1 mice; CYP1A2 N-hydroxylation → 2-chloro-N-hydroxylaniline; ortho-specific nitrenium DNA adduct regiochemistry; metHb former above TLV; SKIN log P 1.90; VP 0.35 mmHg ambient vapor; structural analogy to o-toluidine A2] [4 pts]; three sectors [5 pts]; three sites [3 pts]; FIRST [3 pts]. Total: 21.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."
ORTHO_CHLOROANILINE_THRESHOLD = 21  # OSHA no PEL + NIOSH no REL = double enforcement vacuum; ACGIH TLV-TWA 0.5 ppm A3 SKIN

chemical = "2-chloroaniline_o-chloroaniline_CAS_95-51-2"
osha_pel_ppm = None    # enforcement vacuum — not listed in Z-1, Z-2, or Z-3
acgih_tlv_ppm = 0.5   # A3 SKIN — hepatocellular carcinoma B6C3F1 mice; ortho-chloro nitrenium DNA adducts
niosh_rel_ppm = None   # enforcement vacuum — not in NIOSH Pocket Guide with numerical REL

class OrthoChloroanilineContext(StrEnum):
    LANXESS_BUSHY_PARK_SC_PHARMA      = auto()  # Surface 1 (SKC OVS-2 NIOSH 2002 GC-FID; 1.4→0.14 ppm; 40M 12yr)
    DYSTAR_CHARLOTTE_NC_AZO_DYE       = auto()  # Surface 2 (RAE MiniRAE 3000 PID CF=1.20; 1.2→0.12 ppm; 37F 8yr)
    CAMBREX_CHARLES_CITY_IA_API       = auto()  # Surface 3 (Photovac Voyager PID CF=1.18; 1.0→0.10 ppm; 35M 7yr)

class AdversarialOrthoChloroanilineError(RuntimeError):
    def __init__(self, surface: OrthoChloroanilineContext, score: int, frame_hash: str):
        super().__init__(
            f"2-CA adversarial AI detected [{surface}] "
            f"score={score}/{ORTHO_CHLOROANILINE_THRESHOLD} hash={frame_hash}"
        )

async def scan_2ca_monitor_frame(image_path: Path, surface: OrthoChloroanilineContext) -> dict:
    async with httpx.AsyncClient(timeout=10) as client:
        image_bytes = image_path.read_bytes()
        frame_hash = hashlib.sha256(image_bytes).hexdigest()[:16]
        resp = await client.post(
            GLYPHWARD_API,
            headers={"X-Api-Key": GLYPHWARD_KEY},
            json={
                "image_b64": __import__("base64").b64encode(image_bytes).decode(),
                "context": surface,
                "chemical": chemical,
                "osha_pel_ppm": osha_pel_ppm,
                "acgih_tlv_ppm": acgih_tlv_ppm,
                "niosh_rel_ppm": niosh_rel_ppm,
                "enforcement_vacuum": True,           # BOTH OSHA and NIOSH absent — double enforcement vacuum
                "a3_animal_carcinogen": True,         # hepatocellular carcinoma B6C3F1 mice; ortho-specific nitrenium
                "methemoglobin_former": True,         # CYP1A2 N-hydroxylation → 2-chloro-N-hydroxylaniline
                "skin_notation": True,                # log P 1.90; VP 0.35 mmHg; higher ambient vapor than 4-CA
                "ortho_isomer": True,                 # distinct DNA adduct regiochemistry vs para-isomer 4-CA
                "o_toluidine_structural_analog": True, # CAS 95-53-4 A2 IARC 2B — ortho-methyl vs ortho-chloro
                "threshold": ORTHO_CHLOROANILINE_THRESHOLD,
            },
        )
        result = resp.json()
        if result["score"] >= ORTHO_CHLOROANILINE_THRESHOLD:
            raise AdversarialOrthoChloroanilineError(surface, result["score"], frame_hash)
        return result

See also: Malathion (CAS 121-75-5) — OSHA PEL 15 mg/m³ vs ACGIH TLV-TWA 1 mg/m³ A3 SKIN (15× Gap) + IARC Group 1 NHL · 4-Chloroaniline (p-Chloroaniline; CAS 106-47-8) — OSHA No PEL Enforcement Vacuum vs ACGIH TLV-TWA 0.5 ppm A3 SKIN + Methemoglobin Former · Glyphward scanner · All adversarial injection patterns